NASDAQ:IART Integra LifeSciences (IART) Stock Price, News & Analysis $16.06 +0.37 (+2.36%) Closing price 09/16/2026 04:00 PM EasternExtended Trading$16.02 -0.04 (-0.25%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Integra LifeSciences Stock (NASDAQ:IART) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Integra LifeSciences alerts:Sign Up Key Stats Today's Range$15.65▼$16.2250-Day Range$15.50▼$19.8552-Week Range$8.70▼$20.49Volume1.62 million shsAverage Volume672,137 shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice Target$18.86Consensus RatingReduce Company Overview Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures. The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction. Integra serves hospitals, health systems, specialty clinics and medical professionals through direct sales organizations and distribution partners. Founded in 1989, Integra has built its business through the development and commercialization of biomaterials, implants and surgical technologies, as well as through acquisitions of complementary medical-device businesses. The company serves customers in the United States and international markets, with operations and commercial activities spanning multiple regions worldwide.AI Generated. May Contain Errors. Read More Integra LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreIART MarketRank™: Integra LifeSciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 485th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingReduce Consensus RatingIntegra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, 1 buy rating, 5 hold ratings, and 2 sell ratings.Upside PotentialIntegra LifeSciences has a consensus price target of $18.86, representing about 17.4% upside from its current price of $16.06.Amount of Analyst CoverageIntegra LifeSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Integra LifeSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.47% Earnings GrowthEarnings for Integra LifeSciences are expected to grow by 4.47% in the coming year, from $2.46 to $2.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Integra LifeSciences is -178.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Integra LifeSciences is -178.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioIntegra LifeSciences has a PEG Ratio of 0.81. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioIntegra LifeSciences has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Integra LifeSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.17% of the float of Integra LifeSciences has been sold short.Short Interest Ratio / Days to CoverIntegra LifeSciences has a short interest ratio ("days to cover") of 12.31, which indicates bearish sentiment.Change versus previous monthShort interest in Integra LifeSciences has recently increased by 1.72%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntegra LifeSciences does not currently pay a dividend.Dividend GrowthIntegra LifeSciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.89 News SentimentIntegra LifeSciences has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Integra LifeSciences this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Integra LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.84% of the stock of Integra LifeSciences is held by insiders.Percentage Held by Institutions84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Integra LifeSciences' insider trading history. Receive IART Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IART Stock News HeadlinesIntegra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15 at 9:00 PM | seekingalpha.comQ2 earnings outperformers: Integra LifeSciences (NASDAQ:IART) and the rest of the surgical equipment & consumables - specialty stocksSeptember 10, 2026 | msn.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 17 at 1:00 AM | Decentralized Masters (Ad)Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare ConferenceSeptember 4, 2026 | globenewswire.comIntegra LifeSciences: Strong Q2 2026 Results Support Recovery ThesisSeptember 2, 2026 | seekingalpha.comIntegra (IART) Q2 2026 Earnings Call TranscriptAugust 8, 2026 | finance.yahoo.comIntegra LifeSciences Holdings (IART) Returns To Profit As Fair Value Debate Stays In FocusAugust 3, 2026 | finance.yahoo.comWhy Integra LifeSciences (IART) Trimmed Its 2026 Outlook After Returning to ProfitabilityAugust 2, 2026 | finance.yahoo.comSee More Headlines IART Stock Analysis - Frequently Asked Questions How have IART shares performed this year? Integra LifeSciences' stock was trading at $12.42 at the beginning of 2026. Since then, IART shares have increased by 29.3% and is now trading at $16.06. How were Integra LifeSciences' earnings last quarter? Integra LifeSciences Holdings Corporation (NASDAQ:IART) released its quarterly earnings results on Wednesday, July, 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The life sciences company earned $418.76 million during the quarter, compared to analysts' expectations of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive trailing twelve-month return on equity of 18.30%. Read the conference call transcript. When did Integra LifeSciences' stock split? Integra LifeSciences's stock split before market open on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Integra LifeSciences have any subsidiaries? The following companies are subsidiaries of Integra LifeSciences: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and others. Who are Integra LifeSciences' major shareholders? Integra LifeSciences' top institutional shareholders include Paradigm Capital Management Inc. NY (4.42%), Wellington Management Group LLP (1.88%), Bank of New York Mellon Corp (0.62%) and Assenagon Asset Management S.A. (0.18%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen and Jeffrey A Graves. View institutional ownership trends. How do I buy shares of Integra LifeSciences? Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integra LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD). Company Calendar Last Earnings7/29/2026Today9/17/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IART's financial health is in the Green zone, according to TradeSmith. IART has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:IART CIK917520 Webwww.integralife.com Phone(609) 275-0500Fax609-750-4277Employees4,427Year Founded1989Price Target and Rating Average Price Target for Integra LifeSciences$18.86 High Price Target$25.00 Low Price Target$13.00 Potential Upside/Downside+17.4%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E Ratio6.53 P/E Growth0.81Net Income-$516.47 million Net Margins-0.44% Pretax Margin-0.01% Return on Equity18.30% Return on Assets5.30% Debt Debt-to-Equity Ratio1.75 Current Ratio3.60 Quick Ratio2.11 Sales & Book Value Annual Sales$1.64 billion Price / Sales0.76 Cash Flow$4.32 per share Price / Cash Flow3.72 Book Value$13.40 per share Price / Book1.20Miscellaneous Outstanding Shares77,770,000Free Float74,787,000Market Cap$1.25 billion OptionableOptionable Beta1.21 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IART) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integra LifeSciences Holdings Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Integra LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
